The FDA has granted approval to CELCUITY for its novel oral anti-cancer agent, set to launch on July 14, 2026. This strategic development positions the company to significantly disrupt the mid-to-late-line treatment landscape, potentially driving substantial market share growth ahead of strong anticipated earnings momentum.